ESR1 and breast cancer: An ER+ breast cancer model (Supplementary Fig. 10b) is supported by evidence of increased myeloid inflammatory activity, less metabolically active endothelium, attenuated cancer cell IFN responses, and CD4+/CD8+ T cell quiescence and metabolic dysfunction with age.